Showing results (1341-1350 of 3,105) with videos related to

Sort By:
Pageof 311
Drug Safety|September 29, 2020
Patient Organizations' Barriers in Pharmacovigilance and Strategies to Stimulate Their ParticipationKatherine Chinchilla, Cristiano Matos, Victoria Hall, et al.
Drug Safety|January 14, 2020
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC StudyHans-Christian Kolberg, Marco Colleoni, Georgia Savva Demetriou, et al.
Drug Safety|October 24, 2020
Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS RegistryAlexandra Simbrich, Jasmine Thibaut, Laura Khil, et al.
Drug Safety|September 30, 2020
Assessing the Safety of COVID-19 Vaccines: A PrimerHelen Petousis-Harris
Drug Safety|April 3, 2020
Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in MalawiViviane Jusot, Frider Chimimba, Nettie Dzabala, et al.
Drug Safety|November 28, 2018
Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database: Trends and Specific Signals from a Disproportionality AnalysisKhac-Dung Nguyen, Hoang-Anh Nguyen, Dinh-Hoa Vu, et al.
Drug Safety|January 9, 2019
Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase StudyLotte A Minnema, Thijs J Giezen, Patrick C Souverein, et al.
Drug Safety|January 9, 2019
Identifying Data Elements to Measure Frailty in a Dutch Nationwide Electronic Medical Record Database for Use in Postmarketing Safety Evaluation: An Exploratory StudyJanet Sultana, Ingrid Leal, Marcel de Wilde, et al.
Drug Safety|November 28, 2020
Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018Masao Iwagami, Ryosuke Kumazawa, Yoshihisa Miyamoto, et al.
Drug Safety|November 25, 2020
Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting SystemHenry Trumbo, Karolina Kaluza, Syed Numan, et al.
Pageof 311